47 related articles for article (PubMed ID: 7559192)
1. Postantibiotic, postantibiotic sub-MIC, and subinhibitory effects of PGE-9509924, ciprofloxacin, and levofloxacin.
Odenholt I; Löwdin E; Cars O
Antimicrob Agents Chemother; 2003 Oct; 47(10):3352-6. PubMed ID: 14506057
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection.
Lacy MK; Lu W; Xu X; Tessier PR; Nicolau DP; Quintiliani R; Nightingale CH
Antimicrob Agents Chemother; 1999 Mar; 43(3):672-7. PubMed ID: 10049286
[TBL] [Abstract][Full Text] [Related]
3. Factors influencing fluoroquinolone resistance.
Sahm DF; Thornsberry C; Jones ME; Karlowsky JA
Emerg Infect Dis; 2003 Dec; 9(12):1651-4. PubMed ID: 14725310
[No Abstract] [Full Text] [Related]
4. Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients.
Malone RS; Fish DN; Abraham E; Teitelbaum I
Antimicrob Agents Chemother; 2001 Oct; 45(10):2949-54. PubMed ID: 11557500
[TBL] [Abstract][Full Text] [Related]
5. The Nonantibiotic Macrolide EM703 Improves Survival in a Model of Quinolone-Treated Pseudomonas aeruginosa Airway Infection.
Kasetty G; Bhongir RKV; Papareddy P; Herwald H; Egesten A
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28652240
[TBL] [Abstract][Full Text] [Related]
6. Disposition kinetics of levofloxacin in sheep after intravenous and intramuscular administration.
Goudah A; Hasabelnaby S
Vet Med Int; 2010 Nov; 2010():727231. PubMed ID: 21052556
[TBL] [Abstract][Full Text] [Related]
7. Disposition kinetics and dosage regimen of levofloxacin on concomitant administration with paracetamol in crossbred calves.
Dumka VK
J Vet Sci; 2007 Dec; 8(4):357-60. PubMed ID: 17993749
[TBL] [Abstract][Full Text] [Related]
8. Disposition kinetics, urinary excretion and dosage regimen of levofloxacin formulation following single intravenous administration in crossbred calves.
Dumka VK; Srivastava AK
Vet Res Commun; 2007 Oct; 31(7):873-9. PubMed ID: 17279462
[No Abstract] [Full Text] [Related]
9. Pharmacokinetics, urinary excretion and dosage regimen of levofloxacin following a single intramuscular administration in cross bred calves.
Dumka VK; Srivastava AK
J Vet Sci; 2006 Dec; 7(4):333-7. PubMed ID: 17106223
[TBL] [Abstract][Full Text] [Related]
10. Bactericidal activities of BMS-284756, a novel Des-F(6)-quinolone, against Staphylococcus aureus strains with topoisomerase mutations.
Lawrence LE; Frosco M; Ryan B; Chaniewski S; Yang H; Hooper DC; Barrett JF
Antimicrob Agents Chemother; 2002 Jan; 46(1):191-5. PubMed ID: 11751133
[TBL] [Abstract][Full Text] [Related]
11. In vivo oral efficacy of levofloxacin for treatment of systemic Pseudomonas aeruginosa infections in a murine model of septicemia.
Yagel SK; Barrett JF; Amaratunga DJ; Frosco MB
Antimicrob Agents Chemother; 1996 Dec; 40(12):2894-7. PubMed ID: 9124863
[TBL] [Abstract][Full Text] [Related]
12. In vivo efficacies of levofloxacin and ciprofloxacin in acute murine hematogenous pyelonephritis induced by methicillin-susceptible and-resistant Staphylococcus aureus strains.
Frosco MB; Melton JL; Stewart FP; Kulwich BA; Licata L; Barrett JF
Antimicrob Agents Chemother; 1996 Nov; 40(11):2529-34. PubMed ID: 8913458
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of resistance to three fluoroquinolones: assessment of levofloxacin disk test error rates and surrogate predictors of levofloxacin susceptibility. AST Surveillance Group.
Fuchs PC; Barry AL; Brown SD
Antimicrob Agents Chemother; 1996 Jul; 40(7):1633-9. PubMed ID: 8807053
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapeutic activity of levofloxacin (HR 355, DR-3355) against systemic and localized infections in laboratory animals.
Klesel N; Geweniger KH; Koletzki P; Isert D; Limbert M; Markus A; Riess G; Schramm H; Iyer P
J Antimicrob Chemother; 1995 Jun; 35(6):805-19. PubMed ID: 7559192
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic effect of oral levofloxacin, ciprofloxacin, and ampicillin on experimental murine pneumonia caused by penicillin intermediate Streptococcus pneumoniae for which the minimum inhibitory concentrations of the quinolones are similar.
Ishida Y; Kurosaka Y; Murakami Y; Otani T; Yamaguchi K
Chemotherapy; 1999; 45(3):183-91. PubMed ID: 10224340
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone.
Otani T; Tanaka M; Ito E; Kurosaka Y; Murakami Y; Onodera K; Akasaka T; Sato K
Antimicrob Agents Chemother; 2003 Dec; 47(12):3750-9. PubMed ID: 14638477
[TBL] [Abstract][Full Text] [Related]
17. Activity of levofloxacin, ofloxacin, D-ofloxacin and ciprofloxacin against systemic and respiratory tract infections in laboratory animals.
Klesel N; Geweniger KH; Koletzki P; Isert D; Limbert M; Markus A; Riess G; Schramm H; Seibert G; Iyer P
Drugs; 1995; 49 Suppl 2():211-4. PubMed ID: 8549307
[No Abstract] [Full Text] [Related]
18. Levofloxacin, a broad spectrum anti-infective: from Streptococcus pneumoniae to Pseudomonas aeruginosa.
Schito AM; Schito GC
J Chemother; 2004 Apr; 16 Suppl 2():3-7. PubMed ID: 15255554
[No Abstract] [Full Text] [Related]
19. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.
Croom KF; Goa KL
Drugs; 2003; 63(24):2769-802. PubMed ID: 14664657
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
